AbbVie opens up to bigger deals as competition heats up

AbbVie is looking to make a push this year on new drugs — and it’s ready to spend for it.

According to a report from the Wall Street Journal, AbbVie is keen to replace the potential sales that could be lost from Humira and will be removing its in-house $2 billion limit of the size of its deals to add on more products.